Prostate cancer (PCa) is one of the major public health problems in Western countries. Recently, the TMPRSS2:ERG gene fusion, which results in the aberrant expression of the transcription factor ERG, has been shown to be the most common gene rearrangement in PCa. Previous studies have determined the contributions of this fusion in PCa disease initiation and/or progression in vitro and in vivo. In this study on TMPRSS2:ERG regulation in PCa, we used an androgen receptor and TMPRSS2:ERG fusion double-negative PCa cell model: PC3c. In three cell clones with different TMPRSS2:ERG expression levels, ectopic expression of the fusion resulted in significant induction of cell migration and invasion in a dose-dependent manner. In agreement with this phenotype, high-throughput microarray analysis revealed that a set of genes, functionally associated with cell motility and invasiveness, were deregulated in a dose-dependent manner in TMPRSS2:ERG-expressing cells. Importantly, we identified increased MMP9 (Metalloproteinase 9) and PLXNA2 (Plexin A2) expression in TMPRSS2:ERG-positive PCa samples, and their expression levels were significantly correlated with ERG expression in a PCa cohort. In line with these findings, there was evidence that TMPRSS2:ERG directly and positively regulates MMP9 and PLXNA2 expression in PC3c cells. Moreover, PLXNA2 upregulation contributed to TMPRSS2:ERG-mediated enhancements of PC3c cell migration and invasion. Furthermore, and importantly, PLXNA2 expression was upregulated in metastatic PCa tumors compared with localized primary PCa tumors. This study provides novel insights into the role of the TMPRSS2:ERG fusion in PCa metastasis.
INTRODUCTION
Prostate cancer (PCa) is one of the most prevalent malignancies and a leading cause of cancer-related deaths affecting men in Western countries. 1 Recent PCa cytogenetic and genomic studies have highlighted several critical genomic alterations involved in disease onset and/or progression. 2 Of these, genomic rearrangements leading to the aberrant expression of the E-twenty-six (ETS) family of transcription factors in PCa is considered as a hallmark. 3, 4 The most frequent genomic rearrangement in PCa is the fusion of the ETS-related gene (ERG) with 5'-regulatory elements of the androgen receptor (AR)-responsive transmembrane protease serine 2 (TMPRSS2), which has been identified in 40 to 70% of PCa patient samples. 3 The TMPRSS2:ERG gene fusion leads to aberrant expression of full-length and/or N-terminal-truncated ERG transcription factors in PCa (referred to as TMPRSS2:ERG protein in this study). 5 The association between TMPRSS2:ERG fusion and PCa clinical outcome has not yet been clearly established. Some studies have shown that this gene fusion is not significantly associated with PCa disease progression or prognosis; [6] [7] [8] however, other studies have demonstrated that it is associated with favorable 9, 10 or poor clinical outcomes. [11] [12] [13] [14] [15] [16] Functional studies on the role of TMPRSS2:ERG in PCa have been performed using PCa cell lines as well as mouse models. Although some reports have demonstrated that ectopic TMPRSS2:ERG expression in the prostate is sufficient to induce prostatic intraepithelial neoplasia in mice, a premalignancy form of PCa, 17, 18 others have highlighted how TMPRSS2:ERG expression cooperates with other genomic alterations, such as PTEN haploinsufficiency, constitutive PI3K/AKT activation or AR signaling, to promote PCa cell migration, invasion and disease progression. [19] [20] [21] Using next-generation sequencing technologies, recent studies aiming to identify TMPRSS2:ERG direct target genes in established PCa cell models have provided further evidence that ERG can modulate the output of AR target genes. [22] [23] [24] These studies provide functional insights into the role of TMPRSS2:ERG in PCa initiation and/or progression.
Nevertheless, PCa is considered as a multifocal disease, because primary PCa tumors are mainly composed of multiple, genetically distinct cancer cells. 2, [25] [26] [27] Regarding TMPRSS2:ERG status and the corresponding TMPRSS2:ERG protein expression profile, a significant prevalence of inter-and/or intra-focal heterogeneity has been also observed in several PCa cohorts. [28] [29] [30] [31] This raises the possibility that the differentially expressed TMPRSS2:ERG protein can control variable transcriptional programs in genetically distinct PCa cells. It is therefore necessary to perform studies on different PCa cell models.
In this study, we examined the role of TMPRSS2:ERG using an established PCa cell model, PC3c, which was previously isolated from AR and TMPRSS2:ERG double-negative PC3 cells. 32 In vivo 32 a commonly observed complication in PCa patients with advanced disease. 33 Here, we demonstrate that ectopic expression of TMPRSS2:ERG fusion increases PC3c cell migration and invasion in a dose-dependent manner. High-throughput transcriptomic studies revealed that a set of genes related to cell motility and invasiveness is deregulated in TMPRSS2:ERGexpressing cells in a dose-dependent manner. We further demonstrate that TMPRSS2:ERG directly and positively regulates MMP9 (Metalloproteinase 9) and PLXNA2 (Plexin A2) expression in PC3c cells, and that PLXNA2 upregulation contributes to the TMPRSS2:ERG-mediated PC3c cell migration and invasion.
RESULTS
Ectopic TMPRSS2:ERG expression leads to phenotype changes in PC3c cells Previous studies have identified diverse TMPRSS2:ERG fusion transcripts in human PCa samples, and the most frequent variant is composed of exon 1 of the TMPRSS2 gene (NM_005656) fused to exon 4 of the ERG gene (NM_004449). 5, 34 In addition, the presence of a 72 bp exon in fusion gene transcripts may contribute to a more aggressive phenotype. 35 We therefore used the TMPRSS2:ERG fusion isoform that includes exon 1 of TMPRSS2 fused to exon 4 of ERG with the presence of the 72 bp exon (Figure 1a ).
Three TMPRSS2:ERG-expressing clones were included in this study, designated as H clone (high), M clone (moderate) and L clone (low), according to their ERG messenger RNA (mRNA) expression levels ( Figure 1b ). ERG mRNA levels in H cells were 2-fold and 10-fold higher than in M cells and in L cells, respectively, whereas no endogenous ERG mRNA was found in pcDNA control cells or in parental PC3c cells. In particular, ERG expression in H cells was only about 50% of that in VCaP cells (endogenous TMPRSS2:ERG-expressing PCa cells), and comparable to endogenous full-length ERG expression in HUVEC cells, suggesting that TMPRSS2:ERG expression levels in our cell models were not excessive. As expected, high, moderate and low expression levels of TMPRSS2:ERG protein were only found, respectively, in H, M and L cells, and not in control cells or in parental PC3c cells (Figure 1c ). In addition, compared with VCaP cells, TMPRSS2:ERG expression in H cells was lower (Supplementary Figure S1) .
A comparison of H, M and L cell morphology to that of control cells showed that where control cells were round and clustered, H cells were more elongated and scattered (Figure 2a ). This morphological change was also observed, to a lesser extent, in M cells, but nearly absent in L cells (Figure 2a) . Next, we examined whether the ectopic TMPRSS2:ERG expression could have an impact on PC3c cell proliferation. Surprisingly, no significant cell proliferation changes were observed in H, M and L cells compared with control cells (Figure 2b ), suggesting that TMPRSS2:ERG fusion contributes to PCa initiation and/or progression in a different way. Accordingly, ectopic TMPRSS2:ERG expression significantly increased PC3c cell migration in a membrane-based assay system (Figure 2c ), as well as its invasiveness in a Matrigel-based system (Figure 2d) . Interestingly, among H, M and L cells, the enhancements of cell motility and invasiveness seemed to depend on TMPRSS2:ERG expression levels: compared with control cells, H cells showed the most significant induction of cell migration (3.5-fold) and invasion (7.5-fold); whereas M cell migration (1.7-fold) and invasion (3.4-fold) were higher than those of L cells (migration: 1.2-fold; invasion: 1.2-fold) (Figures 2c and d) . These results provide in vitro evidence that TMPRSS2:ERG promotes, in a dose-dependent manner, PC3c cell migration and invasion, two crucial attributes of cancer cell metastasis.
Genome-wide expression analysis reveals potential TMPRSS2:ERG target genes and their associated cell motility and invasiveness functions To decipher the molecular mechanisms that underlie TMPRSS2:ERG-mediated PC3c cell migration and invasion enhancements, we investigated global gene expression changes in H, M and L cells using Agilent Technologies 44k Whole Human Genome Expression arrays. Compared with control cells, 1673 genes showed significant differential expression (adjusted P-value o0.01) in H cells (809 upregulated genes and 864 downregulated genes) (Figure 3a) , and 446 genes were differentially expressed in M cells (267 upregulated genes and 179 downregulated genes), whereas only 191 genes with differential expression were identified in L cells (101 upregulated genes and 90 downregulated genes). Therefore, the quantity of deregulated genes identified in H, M and L cells also appeared to rely on TMPRSS2:ERG expression levels in PC3c cells.
A comparison of H, M and L cell transcriptomic profiles revealed that 126 genes were commonly deregulated in H, M and L cells (hereafter referred to as 'common deregulated genes'), including 64 common upregulated genes and 62 common downregulated Tables S2 and S3 ). The 'dose-dependent' expression profile of these genes suggested that they could be direct target genes of TMPRSS2:ERG. Among these genes, we noted the striking upregulation of PLAT (Tissue-type plasminogen activator), a well-known TMPRSS2:ERG target gene in PCa. 4, 36, 37 Moreover, the overexpression of some of these genes has been shown to be associated with PCa progression and poor clinical outcomes, such as CD44, 38 MMP9 39 and FSCN1 (Fascin homolog 1). 40 To understand the overall functional significance of these common 126 deregulated genes, we used the DAVID gene ontology (GO) analysis. 41 Among the top GO terms, we noted that 'cell motion', 'cell migration' and 'metalloendopeptidase activity' were upregulated, whereas 'transcription' and 'regulation of apoptosis' were downregulated (Figure 3c ). Taken together, these transcriptomic studies were in agreement with the observed enhancements of PC3c cell migration and invasion, and further highlighted the TMPRSS2:ERG role in the PCa cell metastasis process.
Turning to the identification of TMPRSS2:ERG direct target genes in PCa, we focused on two candidate target genes in the following studies. The first one was MMP9, also known as Gelatinase B, which has been shown to be associated with PCa progression, 39 and also regulated by other ETS transcription factors in diverse types of cancer cells, including PCa. 42, 43 However, it was not clear whether TMPRSS2:ERG could directly regulate MMP9 expression in PCa. The second potential target gene was PLXNA2, a type I transmembrane glycoprotein that functions as a receptor for Semaphorins. Together with other Plexins, it was initially considered to mediate axon guidance during development. 44 However, recent studies have revealed Semaphorin-Plexin signaling outside of the nervous system, providing additional information about this signaling in cancer. 45 For instance, PLXNB1 (Plexin B1) gene mutations in human PCa samples have been shown to be associated with PCa cell motility and invasion enhancements. 46 These findings, together with the phenotype observed in H, M and L cells, prompted us to further investigate whether TMPRSS2:ERG could directly control MMP9 and PLXNA2 expression to increase PCa cell migration and invasion.
MMP9 and PLXNA2 expression levels were associated with TMPRSS2:ERG expression in human PCa samples To investigate whether MMP9 and PLXNA2 are genuine target genes of TMPRSS2:ERG in PCa, we first examined their expression in human PCa samples. We used RNA from a PCa cohort composed of 52 human prostatectomy specimens from the Tumor Tissue Bank, C2RC, Lille University Hospital (CHRU Lille) (Supplementary Table S4 ). Among these PCa samples, we found, using TMPRSS2:ERG-specific primers, 4 32 samples that showed detectable TMPRSS2:ERG fusion transcripts (61.5%). In this PCa cohort, MMP9 and PLXNA2 expression levels were significantly higher in TMPRSS2:ERG-positive PCa samples than in TMPRSS2: ERG-negative samples (P ¼ 0.0055 and Po0.0001, respectively) (Figures 4a and b) .
To further examine the associations between TMPRSS2:ERG and its potential targets, MMP9 and PLXNA2, we performed a two-tailed non-parametric Spearman correlation analysis. Given the heterogeneity of TMPRSS2:ERG transcripts detected in PCa samples, 5, 34 it is difficult to design universal specific primers to accurately quantify total TMPRSS2:ERG expression. We therefore used ERG-specific primers that could detect not only ERG transcripts, but also TMPRSS2:ERG transcripts. Importantly, high ERG expression was detected only in TMPRSS2:ERG-positive PCa samples, whereas ERG expression in fusion-negative PCa samples Figure S2) , suggesting that, in this PCa cohort, high-level ERG transcripts may be a direct consequence of the presence of TMPRSS2:ERG fusion. Spearman correlation analysis showed that MMP9 expression was significantly correlated with ERG expression (R ¼ 0.4287, P ¼ 0.0015) (Figure 4c ), as was PLXNA2 expression (R ¼ 0.6178, Po0.001) (Figure 4d ). Thus, MMP9 and PLXNA2 expression levels were upregulated in TMPRSS2:ERG-positive PCa specimens, and their expression levels were correlated with ERG expression in PCa samples.
TMPRSS2:ERG directly and positively regulates MMP9 expression in PCa cells To determine whether MMP9 gene expression was directly controlled by TMPRSS2:ERG in PCa cells, we first performed a chromatin immunoprecipitation (ChIP) assay in H cells and control cells. By analyzing the promoter region of the MMP9 gene, we found a putative ETS-binding site (EBS) within 1 kb from the MMP9 transcription start site (Figure 5a, top panel) . ChIP assay showed significant binding of TMPRSS2:ERG on this EBS in H cells (Figure 5a , bottom panel), whereas no TMPRSS2:ERG binding was found on this EBS in control cells, or in the promoter region of GAPDH gene, which does not contain any functional EBS, suggesting direct and specific TMPRSS2:ERG binding to the MMP9 promoter region in PC3c cells.
Next, dose-dependent upregulation of MMP9 gene expression was confirmed by reverse transcriptase quantitative PCR (RT-qPCR) in H, M and L cells (Figure 5b ). In addition, we found that ectopic expression of TMPRSS2:ERG in DU145 cells, another AR and fusion double-negative PCa cell model, also resulted in increased MMP9 expression (Figure 5c and Supplementary Figure  S3 ). As it has been shown that secreted MMP9 has an important role in extracellular matrix remodeling during cancer progression, 47 we further investigated secreted MMP9 levels in TMPRSS2:ERG-expressing cells using a gelatin zymography assay. As expected, compared with control cells, more secreted MMP9 was found in TMPRSS2:ERG-expressing H and M cell conditioned mediums (CMs) (Figure 5d ). In particular, the cell gelatin degradation assay highlighted the association between increased MMP9 secretion and the enhancement of gelatin matrix degradation in TMPRSS2:ERG-expressing H cells (Figure 5e and Supplementary Figure S4) . Moreover, the knockdown of TMPRSS2:ERG in H cells using pooled ERG short interfering RNA (siRNA) (Supplementary Figure S5) led to over 40% reduction of MMP9 expression (Figure 5f ), as well as decreased MMP9 secretion (Figure 5g) . Similar results were also observed in M cells (Supplementary Figure S6) as well as in TMPRSS2:ERG-expressing DU145 cells (Supplementary Figure S7) . Taken together, these results indicate that TMPRSS2:ERG is capable to directly and positively regulate MMP9 in PCa cells.
PLXNA2 is directly and positively regulated by TMPRSS2:ERG in PCa cells PLXNA2 is another candidate TMPRSS2:ERG target gene identified by our transcriptomic studies (Figure 3b) , and its expression was found to be upregulated in TMPRSS2:ERG-positive PCa samples and correlated with ERG expression in PCa specimens. A putative EBS, located within 1 kb from the PLXNA2 gene transcription start site, was found in the PLXNA2 promoter region (Figure 6a, top  panel) . The ChIP assay showed significant TMPRSS2:ERG binding on this EBS in H cells, but not in control cells (Figure 6a, bottom  panel) . Moreover, this binding was absent in the irrelevant GAPDH promoter region, indicating TMPRSS2:ERG directly and specifically binds to the PLXNA2 promoter in PC3c cells.
The dose-dependent increase of PLXNA2 expression was then confirmed in TMPRSS2:ERG-expressing H, M and L cells compared with control cells (Figure 6b ). In addition, PLXNA2 upregulation was also observed in TMPRSS2:ERG-expressing DU145 cells (Figure 6c and Supplementary Figure S3 ). An immunofluoresence assay also showed PLXNA2 protein induction in TMPRSS2:ERGexpressing H cells (Figure 6e, left panel) . Importantly, TMPRSS2:ERG knockdown in H cells resulted in about 50% reduction of PLXNA2 mRNA levels (Figure 6d ), as well as PLXNA2 protein immunostaining (Figure 6e, right panel) . Similar results were observed in M cells (Supplementary Figure S6) and TMPRSS2:ERG-expressing DU145 cells (Supplementary Figure S7) . These results therefore highlight that TMPRSS2:ERG can directly and positively regulate PLXNA2 expression in PCa cells. Figure S8b) . Efficient PLXNA2-knockdown effects were as well observed using pooled PLXNA2 siRNA in H cells (Figures 7a and b) .
PLXNA2, but not
In H cells, ERG knockdown dramatically decreased cell migration by over 50% (Figure 7c ), and cell invasion by 70% (Figure 7d ), indicating that the inductions of cell migration and invasion are specific to ectopic TMPRSS2:ERG expression. Surprisingly, MMP9 knockdown had no significant effect on cell migration or invasion in H cells (Supplementary Figure S8c and d ), whereas PLXNA2 knockdown in H cells resulted in a 30% decrease in cell migration ( Figure 7c ) and a 20% decrease in cell invasion (Figure 7d ). Hence, these findings demonstrate that PLXNA2 upregulation, but not MMP9 upregulation, may contribute, at least in part, to TMPRSS2:ERG-mediated induction of PC3c cell migration and invasion in vitro.
Furthermore, increased cell motility and invasiveness are considered as attributes commonly acquired by PCa cells during metastatic progression. 48 Whether PLXNA2 expression is associated with metastatic PCa remains unclear. As the number of lymph node metastatic cases was relatively low in our PCa cohort (Supplementary Table S4 ), we analyzed PLXNA2 expression in microarray data sets from three independent PCa cohorts. [49] [50] [51] As shown in Figures 7e-g, compared with primary PCa samples, PLXNA2 expression levels were significantly higher in the metastatic PCa, substantiating its potential role in PCa metastasis.
DISCUSSION
Although the presence of chromosomal abnormalities have commonly been observed in hematologic malignancies and sarcomas, 52 it was only in 2005, using conceptually new bioinformatics approaches, that the first gene fusions were identified in a large proportion of PCa. 4 While the gene fusions initially found in PCa were ETS transcription factors (ERG and ETV1) fused to the 5'-part of the prostate-specific gene TMPRSS2, it is now clear that they may involve other ETS family members (that is, ETV4, ETV5, ELK4 and FLI1), novel 5 0 -partners and a class of non-ETS-based fusions. 3 However, the TMPRSS2:ERG fusion remains the most prevalent chromosomal rearrangement in PCa. 3 To date, this fusion has been identified not only in androgen-responsive PCa, but also in androgen-refractory PCa. 16 Here, using three AR-negative PC3c cell clones with different TMPRSS2:ERG expression levels, we demonstrated that ectopic expression of TMPRSS2:ERG can induce, in a dose-dependent manner, PC3c cell motility and invasiveness. These findings are in agreement with the role of the TMPRSS2:ERG fusion as revealed using various PCa cell models. 4 17, 18 Given the diverse genetic backgrounds of PCa cell models used in studies, the common function of TMPRSS2:ERG fusion is to improve PCa cell motility and invasiveness. Furthermore, as TMPRSS2:ERG-induced cell migration and invasion have been shown in AR-positive andnegative PCa cells, this function does not seem to be associated with the AR status of PCa cells. Indeed, the TMPRSS2:ERG targets Figure S9) . Increased cell motility and invasiveness are the essential hallmarks of cancer, as well as prerequisites for local tumor progression and metastasis. 48 Interestingly, recent clinical studies also revealed the presence of TMPRSS2:ERG fusion in circulating tumor cells isolated from PCa patients with metastatic disease and in castration-resistant PCa patients. 54, 55 In addition, TMPRSS2:ERG-positive foci in multifocal PCa have a greater predilection for lymph node metastasis. 56, 57 These clinical findings highlight the potential role of TMPRSS2:ERG in PCa metastasis.
Increased cell motility and invasiveness are also associated with cells adopting a mesenchymal phenotype. 58 The epithelialto-mesenchymal transition (EMT) is considered to be one of key steps for cells to acquire metastatic adaptation. 59 Three previous studies have also demonstrated that EMT is one of the consequences of TMPRSS2:ERG expression in PCa cell models. 37, 53, 60 Accordingly, PC3c cells with high TMPRSS2:ERG expression (H cells) demonstrated a more elongated and scattered mesenchymal morphology. However, the absence of differential expression of EMT markers, such as E-Cadherin, Vimentin, Twist1 and Snail in our cell models (Supplementary Figure S10) , raised two questions that need to be addressed in future studies: (1) among our cell models (H, M and L cells), the highest TMPRSS2:ERG expression was only 50% of that found in VCaP cells; is there a threshold of TMPRSS2:ERG expression necessary to induce EMT in PCa cells? (2) is TMPRSS2:ERG-induced EMT independent of AR signaling?
MMP9 expression has been shown to be correlated with increased invasive and metastatic phenotypes in various tumor types, including PCa. 39, 61, 62 Here, we showed that MMP9 was positively and directly regulated by TMPRSS2:ERG in PC3c cells and its expression was correlated with ERG expression in PCa samples. In fact, several transcription factors, such as NF-kB, SP-1, AP-1 and ETS, have been shown to control MMP9 expression in physiological and pathological conditions. [63] [64] [65] Although it has been reported that ETS-1 promotes the invasiveness of paclitaxelresistant and hormone-refractory PCa cells by increasing MMP9 expression, 66 a recent study reported that SPDEF, another ETS transcription factor, suppresses PCa cell invasion through the repression of MMP9 expression. 42 Together with our results, these findings highlight the importance of the functional specificity of ETS transcription factors in controlling MMP9 expression in PCa. Furthermore, although increased secretion of MMP9 and corresponding gelatin matrix degradation were observed in our Similar results have also been observed in TMPRSS2:ERG or ERGexpressing RWPE-1 and BPH-1 cells treated with the pan-MMP inhibitor or a MMP2/9-specific inhibitor, 17, 18 suggesting that, under membrane-based transwell assay systems, increased MMP9 expression is not essential for TMPRSS2:ERG-induced cell migration and invasion. Of particular interest, MMP9 has been shown to trigger the release of the matrix-bound VEGF, thus promoting tumor angiogenesis, 67 and remodeling the prometastatic microenvironment of the metastatic niche. 47, 68 Therefore, future studies are required to determine the role of MMP9 in TMPRSS2:ERG-positive PCa cells using in vivo models.
Plexin receptors and their Semaphorin ligands were initially identified as evolutionarily conserved axon-guidance cues in the nervous system. 69 However, increasing evidence highlights their role outside the nervous system, and particularly in cancer metastasis and progression. 45 In particular, there is supporting evidence that somatic aberrations of Plexins and Semaphorins are involved in pancreatic carcinogenesis. 70 Although their functions are poorly understood in PCa, Plexin receptors and its Semaphorin ligands have been shown to be expressed in diverse PCa cell lines and tissues. 71 The overexpression of PLXNB1 with somatic missense mutations is functionally associated with increased PCa cell motility and invasiveness, as well as disease metastatic progression. 46, 72 We showed in the present study that TMPRSS2:ERG positively and directly regulates PLXNA2 expression in PC3c cells. Interestingly, during mouse 73, 74 and chicken development, 75, 76 the Erg expression profile overlaps with that of Plxna2 in migrating neural crest cells and aorta, suggesting the possible direct regulation of Plxna2 by the Erg transcription factor in development process. Moreover, other transcription factors may also control PLXNA2 expression. For example, GATA6 has been shown to directly regulate PLXNA2 expression during human cardiac outflow tract development. 77 Furthermore, the pleiotropic signals mediated by Semaphorin-Plexin have been shown to positively or negatively control multiple functions in tumor cells, including their migration and invasion abilities. 45 We showed that the upregulation of PLXNA2 contributes, at least in part, to TMPRSS2:ERG-induced PC3c cell migration and invasion. In agreement with these findings in vitro, analysis of microarray data sets provided evidence that PLXNA2 expression is upregulated in metastatic PCa, supporting the potential involvement of PLXNA2 in PCa metastatic spread.
In summary, using an AR-negative PCa model, we confirmed the important role of TMPRSS2:ERG in PCa cell migration and invasion, and identified two 'cell motility'-and 'invasiveness'-related direct target genes, MMP9 and PLXNA2, providing novel insights into the role of TMPRSS2:ERG in PCa metastasis. 
MATERIALS AND METHODS

Cell culture and chemical reagents
Generation of plasmids and retrovirus constructs
The TMPRSS2:ERG complementary DNA (cDNA) was isolated from a fusionpositive PCa patient sample, and subcloned into a pcDNA3.1( þ ) (Invitrogen, Carlsbad, CA, USA) or retrovirus pLPCX vector (Clontech, Mountain View, CA, USA). The primers used for cloning are listed in Supplementary Table S1 . Amplified plasmids were purified on NucleoBond Xtra Midi endotoxin-free columns (Macherey-Nagel, Hoerdt, France) and sequenced before use.
Generation of TMPRSS2:ERG-expressing cells
Low-passage PC3c cells were transfected with a TMPRSS2:ERG expression vector or empty pcDNA vector using FuGENE 6 Reagent (Roche Diagnostics, Indianapolis, IN, USA) according to the manufacturer's instruction, then selected in routine culture medium containing 400 mg/ ml G418 antibiotic (Gibco, Paisley, UK, 11811-031) for 3 weeks. The pLPCXor pLPCX/TMPRSS2:ERG-containing retroviruses were transduced into DU145 cells to generate TMPRSS2:ERG-expressing cells according to the manufacturer's instructions (Clontech).
siRNA transfection
Predesigned pooled siRNA were obtained from Dharmacon-Thermo Scientific (Lafayette, CO, USA). Cells were transfected with the siRNA (50 nM) using Lipofectamine 2000 reagent (Invitrogen) according to the manufacturer's instructions. Gene-knockdown effects were evaluated after 72 h of transfection. The siRNA used in this study were siERG (ONTARGETplus SMARTpool L-003886-00), siMMP9 (ON-TARGETplus SMARTpool L-005970-00), siPLXNA2 (ON-TARGETplus SMARTpool L-021532-01) and the control siRNA (ON-TARGETplus Non-targeting Pool D-001810-10).
Protein extraction and immunoblotting
Proteins were extracted and immunoblotted (western blotting) as described previously. 78 Antibodies used in immunoblotting were: rabbit monoclonal anti-ERG (Epitomics (Burlingame, CA, USA) 2085, dilution 1:1000), mouse monoclonal anti b-actin (Sigma-Aldrich Clone AC-15, dilution 1:10 000), rabbit polyclonal anti HPRT (Santa Cruz (Santa Cruz, CA, USA) sc-20975, dilution 1:1000), Rabbit IgG-HRP (GE Healthcare (Little Chalfont Burkinghamshir, UK) NA934V, dilution 1:10 000) and Mouse IgG-HRP (Santa Cruz, 1:10 000).
Cell proliferation, migration and invasion assay
Cell proliferation assays were performed in quadruplicate using CellTiterGlo kit (Promega, Madison, WI, USA) in 96-well plate (2500 cells/well) according to the manufacturer's recommendations, and luminescence was measured using a Centro LB 960 microplate luminometer (Berthold, Pforzheim, Germany) at indicated times.
Cell migration assays and cell invasion assays were performed with 100 000 cells in triplicate using a FluoroBlok 8-mm pores 24-well insert system (BD Biosciences, Bedford, MA, USA) and 24-well BioCoat Tumor Invasion System (BD Biosciences) according to the manufacturer's instructions. After 16 h of incubation, cells were labeled with 10 mg/ml DilC 12 (3) fluorescent dye (BD Biosciences), and the migrated or invaded cells were measured using a FLUOstar OPTIMA lecturer (BMG Labtech, Ortenberg, Germany).
Gelatin degradation assay and gelatin zymography analysis
Gelatin degradation assay was performed as described previously. 79 To perform the gelatin zymography assay, cells were rinsed and incubated with a medium without fetal bovine serum for 24 h. Then the CMs were collected, and total protein concentrations were measured and used to adjust loading quantity of CM. Equal amount of CMs were mixed with nondenaturing Laemmli blue loading dye, then loaded on a 7% SDS-PAGE gel containing 0.1% (w/v) gelatin. After migration, the gel was incubated with zymogram renaturing buffer and zymogram developing buffer. Finally, the gel was stained with 0.5% (w/v) Coomassie Blue R-250 and destained with a solution containing 40% (v/v) ethanol and 10% (v/v) acetic acid.
Cell total RNA preparation and RT-qPCR Cell total RNA was purified using the NucleoSpin RNA II kit (MachereyNagel) according to the manufacturer's instructions. Then, 1 mg total RNA was used to generate cDNA strand using the High Capacity RNA-to-cDNA kit (Applied Biosystems, Foster City, CA, USA). qPCRs were performed using the Power SYBR Green PCR Master kit (Applied Biosystems) on a Stratagene M Â 3005P qPCR System (Stratagene, La Jolla, CA, USA) according to manufacturer's instructions. Individual gene relative expression level was calculated using the 2 À DDCT method and normalized to that of the housekeeping gene 18S. Optimal primer specificity and efficiency were validated according to the M Â 3005P qPCR System user's guide. The primers used in this study can be found in Supplementary Table S1 .
Immunofluorescence
Immunofluorescence assays were performed as described. 78 The antibodies used in this study were monoclonal rabbit anti-ERG (Epitomics 2805, dilution 1:200), monoclonal rat anti-PLXNA2 (R&D Systems (Minneapolis, MN, USA), MAB5486, 10 mg/ml), Alexa Fluo-488 conjugated anti-rabbit IgG (Invitrogen, dilution 1:500) and Alexa Fluo-555 anti-rat IgG (Invitrogen, dilution 1:500). Images were acquired using an LSM 710 confocal microscopy system and ZEN 2010 software (Carl Zeiss, Oberkochen, Germany).
Microarray analysis
Microarray analyses were conducted following the Two-Color MicroarrayBased Expression Analysis Protocol (Agilent Technologies, Santa Clara, CA, USA). For each sample, 1 mg of total RNA was divided into two equal aliquots to enable technical replication known as 'dye-swap hybridization'. The reverse transcription and the labeling procedure were performed using the protocol recommended by Agilent Technologies (Low RNA Input Fluorescent Linear Amplification Kit). Hybridizations were performed on Agilent Whole Human Genome 44K microarrays for 17 h at 65 1C using the Agilent Gene Expression Hybridization kit. Arrays were washed and scanned using Innoscan 700 (Innopsys, Carbonne, France), and the raw data were processed and normalized using the Limma package (Linear Models for Microarray Data) running under the R environment. GO analysis was performed using the DAVID program as described. 
Chromatin immunoprecipitation
ChIP assay was performed as described. 80 Antibodies used were polyclonal rabbit anti-ERG antibody (Santa Cruz sc-353) or control rabbit IgG antibody (Santa Cruz). The genomic DNA was purified using NucleoSpin Clean-up columns (Macherey-Nagel) according to protocol recommended by the manufacturer. Immunopreciptated genomic DNA was analyzed by PCR and details of the primers used can be found in Supplementary Table S1 .
Human PCa samples Human PCa samples (n ¼ 52) were obtained from the local tumor tissue bank, C2RC (Lille, France), after approval by the internal review board (CSTMT-042, 27/07/2009). Sampled and subsequently frozen tumor tissues originated from radical prostatectomies or trans-urethral prostatic resections performed at Lille University Hospitals (CHRU de Lille). All patients were informed and consent was obtained by the referring physician. To extract RNA, tissue samples were first homogenized in TRIzol (Invitrogen), and total RNA was prepared using NucleoSpin RNA II columns (MachereyNagel). The RNA quality and quantity were accessed by the Agilent 2100 Bioanalyser system. Pathological findings of these PCa samples can be found in Supplementary Table S4 .
Image treatment and statistical analysis All image treatments were carried out using Image J or Photoshop CS software (Adobe, San Jose, CA, USA). Statistical analysis was performed using GraphPad Prism software (San Diego, CA, USA). Statistical methods used in this study are indicated in the corresponding figure legends. Unless otherwise indicated, all values in the figures are expressed as means±s.e.m.
